Sector News

Andrew Cheng to quit Gilead 6 months after taking CMO post

August 15, 2018
Life sciences

Andrew Cheng, M.D., Ph.D., is set to leave Gilead six months after being appointed CMO. Cheng’s swift exit keeps the revolving door spinning at the top of Gilead, which is set to lose its CEO, CMO, CSO and executive chairman over a nine-month window.

Gilead named Cheng as CMO in March, 19 years after he joined the company. Cheng started out as the leader of Gilead’s development-stage HIV programs and went on to take on more responsibilities in 2009. Gilead promoted Cheng to an EVP post in 2015 before bumping him up to the CMO chair in March.

Now, Cheng is set to step down to take up an as-yet-unnamed opportunity. Cheng will stick around until September to help with the transition, after which he will leave and presumably later pop up at a new employer.

The imminent loss of Cheng adds to the upheaval in Gilead’s C-suite. John Martin, Ph.D., began the period of change by stepping down as executive chairman in March. The following month, Norbert Bischofberger, Ph.D., vacated the CSO chair. In July, John Milligan, Ph.D., furthered the turnover by revealing he will step down as CEO of Gilead at the end of the year after 28 years at the company.

Gilead broke news of Cheng’s departure in a statement that revealed appointments elsewhere in the organization. Diana Brainard, M.D., is stepping up to the role of SVP, HIV and emerging viral infections after eight years at the company. And Gregg Alton is taking on the chief patient officer job.

Alton’s appointment hands new responsibilities to a 20-year Gilead veteran who has been the one constant at the top of the company during a period of change. Of the people who held the top five positions in Gilead’s organizational chart at the start of 2018, only Alton looks likely to begin next year at the company.

By Nick Paul Taylor

Source: Fierce Biotech

comments closed

Related News

November 27, 2022

DSM-Firmenich nutrition and beauty mega-merger edges closer as companies announce Exchange Offer

Life sciences

The new company will have four complementary businesses: Perfumery & Beauty, Food & Beverage/Taste & Beyond, Health, Nutrition & Care and Animal Nutrition & Health, each with strong market positions and expertise to address emerging consumer trends. The businesses will also prioritize environmental sustainability, health and well-being.

November 27, 2022

Merck agrees to acquire Imago for $1.35bn

Life sciences

Merck (MSD) has signed a definitive agreement for the acquisition of all outstanding shares of Imago BioSciences for a total equity price of nearly $1.35bn. A clinical-stage biopharmaceutical firm, Imago focuses on the development of new therapies to treat myeloproliferative neoplasms (MPNs) and other bone marrow ailments.

November 27, 2022

Novo Nordisk expands API capacity

Life sciences

Danish pharma Novo Nordisk has announced plans to invest 5.4 billion Danish kroner to expand its existing facilities in Bagsværd. The project will establish extra R&D capacity for manufacturing APIs to supply the company’s global clinical trials for oral and injectable products. The expansion is expected to be finished in 2024, creating about 160 new jobs.